What Factors Affect Treatment Decisions in Patients With HS? What Factors Affect Treatment Decisions in Patients With HS?
Dermatologists can empower patients to make informed, meaningful treatment choices, the authors said.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 11, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Study Identifies CV Comorbidities Linked to Dermatomyositis Study Identifies CV Comorbidities Linked to Dermatomyositis
The results " represent potential areas for preventative intervention, " the researchers wrote.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 8, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
FDA Gives Nod to Berdazimer Gel for Molluscum Contagiosum FDA Gives Nod to Berdazimer Gel for Molluscum Contagiosum
The topical treatment is expected to be commercially available in the second half of 2024.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 6, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Expert Highlights Biologics in the Pipeline for Eczema Expert Highlights Biologics in the Pipeline for Eczema
Dr David Rosmarin reviewed several biologics in clinical trials that target interleukin-4 and other receptors.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 5, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
US Dermatologic Drug Approvals Rose Between 2012 and 2022 US Dermatologic Drug Approvals Rose Between 2012 and 2022
Of the 52 new drugs approved in the past decade, 21% were categorized as first in class, but more innovations are needed for skin diseases with unmet therapeutic needs, the authors said.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 4, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Experimental Topical Drug Shows Promise for AD, Psoriasis Experimental Topical Drug Shows Promise for AD, Psoriasis
In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 4, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Long COVID Has Caused Thousands of US Deaths: New CDC Data Long COVID Has Caused Thousands of US Deaths: New CDC Data
Fresh estimates from the CDC show a growing death tally from long COVID —– with numbers expected to increase as diagnostic expertise improves.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 3, 2024 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
5-Year Safety Data From Upadacitinib Trials Reported 5-Year Safety Data From Upadacitinib Trials Reported
Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 3, 2024 Category: Allergy & Immunology Tags: Dermatology Source Type: news
Long COVID: New Info on Who Is Most Likely to Get It Long COVID: New Info on Who Is Most Likely to Get It
Fresh research and clinical anecdotes have given experts a much clearer picture of which patients are most likely to develop long COVID.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 27, 2023 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
The 2024 Adult Vaccine Schedule Changes Are Here The 2024 Adult Vaccine Schedule Changes Are Here
Usually posted in February, the 2024 schedule has arrived early. Dr Sandra Fryhofer goes over the key changes in the adult schedule for 2024.Medscape Internal Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 26, 2023 Category: Allergy & Immunology Tags: Internal Medicine Practice Guideline Source Type: news
US FDA Approves Sweden-based Calliditas' Kidney Disease Drug US FDA Approves Sweden-based Calliditas' Kidney Disease Drug
The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics ' drug to treat rare kidney disease IgA Nephropathy (IgAN), the...Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 20, 2023 Category: Allergy & Immunology Tags: Nephrology Source Type: news
COPD: Tips on Primary Care Management COPD: Tips on Primary Care Management
Changes in the lungs with aging can make COPD diagnosis more challenging. These tools and resources are invaluable.The Curbsiders (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 20, 2023 Category: Allergy & Immunology Tags: Internal Medicine Commentary Source Type: news
Recent TB Infection Rare Among Immigrants to Canada Recent TB Infection Rare Among Immigrants to Canada
Data suggest that few immigrants to Canada with tuberculosis infection were infected within the preceding 2 years, when the risk for progression to tuberculosis disease is the highest.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 19, 2023 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
Infections Down in Acute Care Hospitals Infections Down in Acute Care Hospitals
Prevention strategies to reduce healthcare-associated infections are having an effect, according to a new report on national- and state-level incidence.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 18, 2023 Category: Allergy & Immunology Tags: Infectious Diseases Source Type: news
FDA Approves Tralokinumab for Treating Eczema in Adolescents FDA Approves Tralokinumab for Treating Eczema in Adolescents
It is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis that specifically targets the interleukin (IL)-13 cytokine.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 16, 2023 Category: Allergy & Immunology Tags: Dermatology Source Type: news
